Arcutis Swings to Profit in Q2 as ZORYVE Revenue Surges 59%
ARQT has more than doubled off its 52-week low of $13.695.
Summary
Arcutis Biotherapeutics reported Q2 2026 net income of $15.0 million on product revenue of $129.9 million, a 59% increase year-over-year, driven by strong ZORYVE sales. The company also disclosed new 10b5-1 trading plans for its CEO and CLO.
Key Events · Earnings and Guidance · ARQT
-
Q2 Revenue Surges 59%
Driven by ZORYVE foam and cream formulations, product revenue reached $129.9 million, up from $81.5 million in Q2 2025.
-
Swings to Profitability
Marking a significant inflection, net income was $15.0 million, compared to a net loss of $15.9 million in the prior-year quarter.
-
Strong Cash Position
As of June 30, 2026, cash, equivalents, restricted cash, and marketable securities totaled $238.9 million, providing at least 12 months of runway.
-
Insider Trading Plans Adopted
CEO Todd Watanabe adopted a 10b5-1 plan for up to 325,000 options, and CLO Masaru Matsuda adopted a plan for up to 40,000 options and 45,792 shares, both effective in late August/September 2026.
Analysis · ARQT · Life Sciences
For the first time in recent history, Arcutis delivered a profitable quarter, fueled by robust ZORYVE demand across all formulations. Product revenue jumped 59% year-over-year to $129.9 million, flipping a $15.9 million net loss into a $15.0 million net profit. The quarter ended with $238.9 million in cash and investments, providing ample runway. However, the CEO and CLO adopted new 10b5-1 trading plans in June, signaling potential future insider sales that could weigh on sentiment.
At the time of this filing, ARQT was trading at $29.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4B. The 52-week trading range was $13.70 to $31.77. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.